Document:

exv10w38

 

Exhibit 10.38

INDEMNITY AGREEMENT

THIS AGREEMENT is entered into on the                 day of October, 2007,

	 	 	 
	BETWEEN:
	 	 
	 

	 	ASPREVA PHARMACEUTICALS CORPORATION, a company incorporated under
the laws of British Columbia, and having its registered office at
2500-700 West Georgia Street, Vancouver, BC, V7Y 1B3
	 

	 	(the “Company”)
	AND:
	 	 
	 

	 	 

	 

	 	(the “Indemnitee”)

     WHEREAS, the Indemnitee has agreed to serve, or to continue to serve, as a Director or
Officer, subject to the Company providing the Indemnitee with the indemnity provided herein;

     AND WHEREAS in order to induce the Indemnitee to serve, or to continue to serve, as a Director
or Officer, the Company has agreed to provide the Indemnitee with the indemnity provided herein;

     NOW THEREFORE, in consideration of the Indemnitee agreeing to serve or continue to serve as a
Director or Officer, as set out above, and the premises and the mutual covenants and agreements
contained herein and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto agree as follows:

	1.	 	AGREEMENT. This Agreement shall supersede and replace entirely all prior agreements entered
into between the Indemnitee and the Company relating to the subject matter hereof.

	2.	 	DEFINITIONS. In this Agreement, except as otherwise expressly provided:

	 	(a)	 	the term “Associated Corporation” means a corporation or entity referred to in
paragraph (c)(ii) and (iii);
	 
	 	(b)	 	the terms “corporation” and “director” shall have the meanings as defined in
the Business Corporations Act (British Columbia), as amended from time to time, or any
successor legislation;
	 
	 	(c)	 	the terms “Director” and “Officer” include an individual who:

	 	(i)	 	is or was a director or officer of the Company;
	 
	 	(ii)	 	is or was a director or officer of another corporation:

 

 

	 	A.	 	at a time when the corporation is or was an
affiliate of the Company as defined in the Business Corporations Act
(British Columbia), as amended from time to time, or any successor
legislation; or
	 
	 	B.	 	at the request of the Company; or
	 
	 	C.	 	at the request of the Company, is or was, or
holds or held a position equivalent to that of, a director or officer
of a partnership, trust, joint venture or other unincorporated entity;

	 	(d)	 	the term “Eligible Penalty” means a judgment, penalty or fine awarded or
imposed in, or any amount paid in settlement of, an Eligible Proceeding;
	 
	 	(e)	 	the term “Eligible Proceeding” means a proceeding in which the Indemnitee or
any of the heirs and personal or other legal representatives of the Indemnitee, by
reason of the Indemnitee being or having been a director or officer of, or holding or
having held a position equivalent to that of a director or officer of, the Company or
an Associated Corporation:

	 	(i)	 	is or may be joined as a party; or
	 
	 	(ii)	 	is or may be liable for or in respect of a judgment, penalty or
fine in, or expenses related to, the proceeding;

	 	(f)	 	the term “Expenses” includes costs, charges and expenses, including legal and
other fees, but does not include judgments, penalties, fines or amounts paid in
settlement of a proceeding;
	 
	 	(g)	 	the term “Proceeding” includes any legal proceeding or investigative action,
whether current, threatened, pending or completed; and
	 
	 	(h)	 	the term “Indemnitee” includes, except (i) where referred to in the preambles,
(ii) in the definition of “Eligible Proceeding” and (iii) in sections 3(d) and (i), and
sections 5(c) and (d), the heirs and personal or other representatives of the
Indemnitee.

	3.	 	GENERAL INDEMNITY. The Company agrees, subject to the provisions of sections 5 and 6, to
indemnify and save the Indemnitee harmless, to the full extent permitted by law, including but
not limited to the extent permitted under the Business Corporations Act (British Columbia), as
the same exists on the date hereof or may hereafter be amended (but, in the case of such
amendment, only to the extent that such amendment permits the Company to provide broader
indemnification rights than the law permitted prior to such amendment) from and against:

	 	(a)	 	any and all costs, charges, expenses, fees, damages or liabilities (including
legal or other professional fees and disbursements); and

2

 

	 	(b)	 	without limitation of section 3(a), all statutory obligations to creditors,
employees, suppliers, contractors, subcontractors, and any government or any agency or
division of any government, including, without limitation, any federal, provincial,
state, regional or municipal government;

regardless of when they arose and howsoever arising, and whether arising in law, equity,
under statute, regulation or ordinance, and in whatever jurisdiction and whether incurred
alone or jointly with others, which the Indemnitee may suffer, sustain, incur or be required
to pay arising out of or incurred in respect of any action, suit, proceeding, arbitration,
assessment, order, investigation, discovery, enquiry, hearing or claim, whether civil,
criminal, administrative or other process howsoever arising (each of which is hereinafter
referred to as a “Claim”), and arising out of or in connection with:

	 	(c)	 	the affairs of the Company or any Associated Corporation; or
	 
	 	(d)	 	the exercise by the Indemnitee of the Indemnitee’s powers or the performance of
the Indemnitee’s duties as a Director or Officer;

     which may be brought, commenced, made, prosecuted or threatened against:

	 	(e)	 	the Indemnitee; or
	 
	 	(f)	 	the Company or any Associated Corporation; or
	 
	 	(g)	 	any subsidiary of the Company or other entity in which the Company may have an
interest (an “Other Entity”); or
	 
	 	(h)	 	any of the other directors or officers of the Company or any Associated
Corporation or Other Entity or any person acting in a similar capacity;

for or in respect of which:

	 	(i)	 	the Indemnitee is made a party by reason of the Indemnitee being a Director or
Officer or otherwise having been a director or employee or officer of the Company or
any Associated Corporation (or at the request of the Company a director or officer of
or in a similar capacity with any Other Entity); or
	 
	 	(j)	 	the Indemnitee may or may be required to participate, whether by providing
evidence or otherwise;

including, without limitation, any and all costs, charges, expenses, fees, damages or
liabilities which the Indemnitee may suffer, sustain or incur or be required to pay in
connection with investigating, initiating, defending, appealing, preparing for, providing
evidence in, instructing and receiving the advice of the Indemnitee’s own or other counsel
or other professional advisor, or any amount paid to settle any Claim or satisfy any
judgment, fine or penalty.

	4.	 	INDEMNITY OF DIRECTOR OR OFFICER. Without limiting the generality of the foregoing, subject
to sections 5 and 6, the Company shall indemnify the Indemnitee

3

 

	 	 	against each Eligible Penalty to which the Indemnitee is or may be liable and, after the
final disposition of an Eligible Proceeding, shall pay the Expenses actually and reasonably
incurred by the Indemnitee in respect of that proceeding.

	5.	 	LIMITATIONS ON INDEMNITY. Notwithstanding any other provisions of this Agreement, the
Company shall not indemnify the Indemnitee against any Eligible Penalty pursuant to section 4
or pay any Expenses of the Indemnitee pursuant to sections 4, 7 or 8:

	 	(a)	 	if the indemnity or payment is made under an earlier agreement to indemnify or
pay Expenses and, at the time that the agreement to indemnify or pay Expenses was made,
the Company was prohibited from giving the indemnity or paying the Expenses by its
notice of articles or articles;
	 
	 	(b)	 	if the indemnity or payment is made otherwise than under an earlier agreement
to indemnify or pay Expenses and, at the time that the indemnity or payment is made,
the Company is prohibited from giving the indemnity or paying the Expenses by its
notice of articles or articles;
	 
	 	(c)	 	if, in relation to the subject matter of an Eligible Proceeding, the Indemnitee
did not act honestly and in good faith with a view to the best interests of the Company
or the Associated Corporation, as the case may be;
	 
	 	(d)	 	in the case of an Eligible Proceeding other than a civil proceeding, if the
Indemnitee did not have reasonable grounds for believing that the Indemnitee’s conduct
in respect of which the proceeding was brought was lawful; or
	 
	 	(e)	 	if an Eligible Proceeding is brought against the Indemnitee by or on behalf of
the Company or by or on behalf of an Associated Corporation, in respect of the
proceeding.

	6.	 	EXCLUSION TO INDEMNITY. Notwithstanding any other provision of this Agreement, the Company
will not be obligated under this Agreement to indemnify the Indemnitee for any costs, charges,
expenses, fees, damages, liabilities or Eligible Penalty (herein referred to as “Liabilities”)
or pay Expenses of the Indemnitee:

	 	(a)	 	if the Company is prohibited by applicable law from providing such indemnity or
making such payments;
	 
	 	(b)	 	if such Liabilities or payments have been paid to, or on behalf of, the
Indemnitee under an insurance policy, except in respect of any excess beyond the amount
paid under such insurance;
	 
	 	(c)	 	for which Liabilities or payments the Indemnitee is indemnified by the Company
otherwise than pursuant to this Agreement; or
	 
	 	(d)	 	resulting from a claim decided in an Eligible Proceeding adversely to the
Indemnitee based upon or attributable to the Indemnitee gaining in fact any personal
profit or advantage to which the Indemnitee was not legally entitled,

4

 

	 	 	 	including any profits made from the purchase or sale by the Indemnitee of securities
of the Company.

	7.	 	MANDATORY PAYMENT OF EXPENSES. Subject to sections 5 and 6, the Company shall, after the
final disposition of an Eligible Proceeding, pay the Expenses actually and reasonably incurred
by the Indemnitee in respect of that proceeding if the Indemnitee:

	 	(a)	 	has not been reimbursed for those Expenses, and
	 
	 	(b)	 	is wholly successful, on the merits or otherwise, in the outcome of the
Eligible Proceeding or is substantially successful on the merits in the outcome of the
Eligible Proceeding.

	8.	 	ADVANCE PAYMENT OF EXPENSES. Subject to sections 5 and 6, the Company shall pay, as they are
incurred in advance of the final disposition of an Eligible Proceeding, Expenses actually and
reasonably incurred by an Indemnitee in respect of that proceeding; provided, however, that
Expenses of defence need not be paid as incurred and in advance where a court of competent
jurisdiction has decided that the Indemnitee is not entitled to be advanced such Expenses or
indemnified pursuant to this Agreement. The Indemnitee hereby agrees and undertakes to repay
such amounts advanced if it is ultimately determined that the payment of Expenses is
prohibited as contemplated in sections 5 or 6 or that the Indemnitee is not entitled to be
indemnified by the Company pursuant to this Agreement.

	9.	 	ENFORCEMENT. If a claim under this Agreement is not paid by the Company, or on its behalf,
within thirty days after a written claim has been received by the Company, the Indemnitee may
at any time thereafter bring suit against the Company to recover the unpaid amount of the
claim and if successful in whole or in part, the Indemnitee shall also be entitled to be paid
the Expenses of prosecuting such claim.

	10.	 	SUBROGATION. In the event of payment under this Agreement, the Company shall be subrogated
to the extent of such payment to all of the rights of recovery of the Indemnitee, who shall
execute all papers required and shall do everything that may be necessary to secure such
rights, including the execution of such documents necessary to enable the Company effectively
to bring suit to enforce such rights.

	11.	 	NOTICE. The Indemnitee, as a condition precedent to the Indemnitee’s right to be indemnified
under this Agreement, shall give to the Company notice in writing as soon as practicable of
any claim made against the Indemnitee for which indemnity will or could be sought under this
Agreement. Notice to the Company shall be given at its principal office and shall be directed
to the Corporate Secretary (or such other address as the Company shall designate in writing to
the Indemnitee); notice shall be deemed received if sent by prepaid mail properly addressed,
the date of such notice being the date postmarked. In addition, the Indemnitee shall give the
Company such information and co-operation as it may reasonably require.

	12.	 	INDEMNIFICATION HEREUNDER NOT EXCLUSIVE. Nothing herein shall be deemed to diminish or
otherwise restrict the Indemnitee’s right to indemnification under

5

 

any provision of the notice of articles or articles of the Company or under applicable
corporate law.

	13.	 	CONTINUATION OF INDEMNIFICATION. The indemnification under this Agreement shall continue as
to the Indemnitee even though the Indemnitee may have ceased to be a Director or Officer and
shall enure to the benefit of the heirs and personal representatives of the Indemnitee.

	14.	 	COVERAGE OF INDEMNIFICATION. The indemnification under this Agreement shall cover the
Indemnitee’s service as a Director or Officer prior to or after the date of the Agreement.

	15.	 	APPLICABLE LAW. This Agreement shall be governed by and construed in accordance with the
laws of the Province of British Columbia and the federal laws of Canada applicable therein and
the parties hereto attorn to the exclusive jurisdiction of the provincial and federal courts
of British Columbia.

	16.	 	BENEFIT. This Agreement shall enure to the benefit of and be binding upon the parties and
their respective heirs, executors, administrators, successors and assigns.

	17.	 	SEVERABILITY. If any provision of this Agreement is determined at any time by a court of
competent jurisdiction to be invalid, illegal or unenforceable such provision or part thereof
shall be severable from this Agreement and the remainder of this Agreement will be construed
as if such invalid, illegal or unenforceable provision or part thereof had been deleted
herefrom.

	18.	 	FURTHER ASSURANCES. Each party agrees to take all such actions and execute all such
documents within its power as may be necessary or desirable to carry out or implement and give
full effect to the provisions and intent of this Agreement.

	19.	 	TIME OF ESSENCE. Time is the essence of this Agreement and no extension of time shall
constitute a waiver of this provision.

	20.	 	WAIVERS. No waiver of, no consent with respect to, and no approval required under any
provision of this Agreement will be effective unless in writing executed by the party against
whom such waiver, consent or approval is sought to be enforced, and then any such waiver,
consent or approval will be effective only in the specific instance and for the specific
purpose given.

	21.	 	FACSIMILE AND COUNTERPARTS. This Agreement may be executed by facsimile and in one or more
counterparts, each of which when taken together will constitute this Agreement.

6

 

IN WITNESS WHEREOF the parties have executed this Agreement.

	 	 	 	 	 	 	 
	ASPREVA PHARMACEUTICALS CORPORATION
	 	 	 	 	 	 
	Per: __________________________ 	 	 
	         Authorized Signatory
	 	 	 	 	 	 
	SIGNED, SEALED AND DELIVERED by

	 	 	)	 	 	 
	_______________ in the presence of:

	 	 	)	 	 	 
	

	 	 	)	 	 	 
	Name

	 	 	)	 	 	 
	

	 	 	)	 _________________________	 	 
	Address

	 	 	)	 	 	 
	

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	Occupation

	 	 	)exv4w4

 

Exhibit 4.4

STOCK PURCHASE AGREEMENT

by and between

ARCHEMIX CORP.

and

NUVELO, INC.

Dated as of [_______________]

 

 

Table Of Contents

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	SECTION 1 Definitions	 	 	1	 
	SECTION 2 Authorization, Purchase and Sale of the Shares	 	 	3	 
	 
	 	2.1	 	Purchase and Sale of the Shares	 	 	3	 
	 
	 	2.2	 	Closing	 	 	3	 
	SECTION 3 Representations and Warranties and Certain Covenants of the Company	 	 	3	 
	 
	 	3.1	 	Organization, Qualifications and Corporate Power	 	 	3	 
	 
	 	3.2	 	Authorization of Agreements, Etc.	 	 	3	 
	 
	 	3.3	 	Validity	 	 	4	 
	 
	 	3.4	 	Consents	 	 	4	 
	 
	 	3.5	 	Subsidiaries	 	 	4	 
	 
	 	3.6	 	Capitalization	 	 	4	 
	 
	 	3.7	 	Litigation	 	 	5	 
	 
	 	3.8	 	Financial Statements	 	 	5	 
	 
	 	3.9	 	Taxes	 	 	5	 
	 
	 	3.10	 	Intellectual Property	 	 	5	 
	 
	 	3.11	 	Brokers	 	 	5	 
	 
	 	3.12	 	Insurance	 	 	5	 
	 
	 	3.13	 	Prospectus	 	 	6	 
	 
	 	3.14	 	Offering Valid	 	 	6	 
	SECTION 4 Representations and Warranties of Purchaser	 	 	6	 
	 
	 	4.1	 	Experience	 	 	6	 
	 
	 	4.2	 	Investment	 	 	6	 
	 
	 	4.3	 	Rule 144	 	 	6	 
	 
	 	4.4	 	Access to Data	 	 	6	 
	 
	 	4.5	 	Brokers	 	 	6	 
	 
	 	4.6	 	Authorization	 	 	6	 
	SECTION 5 Purchaser’s Conditions to Closing	 	 	7	 
	 
	 	5.1	 	Representations and Warranties	 	 	7	 
	 
	 	5.2	 	Performance	 	 	7	 
	 
	 	5.3	 	Legal Investment	 	 	7	 

(i)

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	 
	 	5.4	 	Rights Agreement	 	 	7	 
	 
	 	5.5	 	Proceedings and Documents	 	 	7	 
	 
	 	5.6	 	Qualifications	 	 	7	 
	 
	 	5.7	 	Qualified IPO	 	 	7	 
	 
	 	5.8	 	Legal Opinion	 	 	7	 
	SECTION 6 Company’s Conditions to Closing	 	 	8	 
	 
	 	6.1	 	Representations and Warranties	 	 	8	 
	 
	 	6.2	 	Performance	 	 	8	 
	 
	 	6.3	 	Legal Investment	 	 	8	 
	 
	 	6.4	 	Rights Agreement	 	 	8	 
	 
	 	6.5	 	Payment of Purchase Price	 	 	8	 
	SECTION 7 Miscellaneous	 	 	8	 
	 
	 	7.1	 	Governing Law	 	 	8	 
	 
	 	7.2	 	Survival	 	 	8	 
	 
	 	7.3	 	Successors and Assigns	 	 	8	 
	 
	 	7.4	 	Entire Agreement; Amendment and Waiver	 	 	9	 
	 
	 	7.5	 	Notices	 	 	9	 
	 
	 	7.6	 	Delays or Omissions	 	 	10	 
	 
	 	7.7	 	Severability	 	 	10	 
	 
	 	7.8	 	Interpretation	 	 	10	 
	 
	 	7.9	 	Further Assurances	 	 	10	 
	 
	 	7.10	 	Headings	 	 	10	 
	 
	 	7.11	 	Counterparts	 	 	10	 

Exhibits

Exhibit A — Registration Rights Agreement

Schedules

[Disclosure Schedule]

(ii)

 

ARCHEMIX CORP.

STOCK PURCHASE AGREEMENT

     THIS STOCK PURCHASE AGREEMENT dated as of [_______] (the “Agreement”) is made by and between
Archemix Corp., a Delaware corporation (the “Company”), and Nuvelo, Inc., a Delaware corporation
(the “Purchaser”).

     WHEREAS, the Company desires to issue and sell to the Purchaser, and the Purchaser desires to
purchase, shares of the Company’s common stock, par value $.001 per share (“Common Stock”), as
provided in Section 7.3 of that certain Amended and Restated Collaboration and License Agreement
between the Company and the Purchaser dated July 31, 2006;

     NOW, THEREFORE, in consideration of the premises and mutual agreements set forth herein and
for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually
acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows:

SECTION 1

Definitions

     1.1 For purposes of this Agreement, the following terms shall have the meanings set forth
below:

          (a) “Act” shall mean the Securities Act of 1933, as amended, or any similar federal statute
and the rules, regulations and policies of the Commission thereunder, all as the same shall be in
effect at the time.

          (b) “Affiliate” shall mean an individual, trust, business trust, joint venture, partnership,
corporation, limited liability company, association or any other entity which (directly or
indirectly) is controlled by, controls or is under common control with the Purchaser. For the
purposes of this definition, the term “control” (including, with correlative meanings, the term
“controlled by” and “under common control with”) as used with respect to the Purchaser, means the
possession of the power to direct or cause the direction of the management and policies of an
entity, through the ownership of the outstanding voting securities or by contract or otherwise.

          (c) “By-laws” shall mean the Amended and Restated By-Laws of the Company, as amended from
time to time.

          (d) “Certificate of Incorporation” shall mean the Company’s Restated Certificate of
Incorporation on file with the Secretary of State of the State of Delaware, as amended from time
to time.

          (e) “Closing” and “Closing Date” shall have the meanings specified in Section 2.2 hereof.

 

 

          (f) “Commission” shall mean the Securities and Exchange Commission or any other federal
agency at the time administering the Act.

          (g) “Common Stock” shall have the meaning specified in the recitals.

          (h) “Purchase Price” shall have the meaning specified in Section 2.1 hereof.

          (i) “Prospectus” shall mean the prospectus contained in the Registration Statement.

          (j) “Qualified IPO” means the Company’s firm commitment underwritten initial public offering
on the New York Stock Exchange, the American Stock Exchange or the NASDAQ Global Market filed
under the Securities Act of 1933, as amended, covering the offer and sale of Company Common Stock,
with total gross offering proceeds to Company (prior to underwriter commissions and expenses) of
at least thirty million dollars ($30,000,000) exclusive of the Purchase Price.

          (k) “Registration Statement” shall mean the Registration Statement on Form S-1 (File No.
333-144837) filed with the Commission relating to the Company’s initial public offering of
its Common Stock.

          (l) “Rights Agreement” shall mean the Registration Rights Agreement dated as of the date
hereof by and between the Company and the Purchaser in the form attached hereto as Exhibit
A.

          (m) “Shares” shall have the meaning specified in Section 2.1 hereof.

     1.2 Certain other words and phrases are defined or described elsewhere in this Agreement and
the Exhibits and Schedules hereto.

     1.3 Wherever used in this Agreement:

          (n) the words “include” or “including” shall be construed as also incorporating “but not
limited to” and “without limitation”;

          (o) the word “day” means a calendar day unless specified otherwise; and

          (p) the word “law” (or “laws”) means any statute, ordinance, regulation or code.

     1.4 Unless specified to the contrary, references to Articles, Sections, Schedules and/or
Exhibits mean the particular Article, Section, Schedule or Exhibit in or to this Agreement.

     1.5 References to this Agreement shall include this Agreement as varied or modified from time
to time by the parties.

     1.6 Unless the context requires otherwise, words in the singular number include the plural and
vice versa.

2

 

     1.7 All Schedules and Exhibits hereto are hereby incorporated herein and made a part hereof.

SECTION 2

Authorization, Purchase and Sale of the Shares

     2.1 Purchase and Sale of the Shares. At the Closing (as defined in Section 2.2
hereof), and subject to the terms and conditions hereof and in reliance upon the representations,
warranties and agreements contained herein, the Company shall issue and sell to the Purchaser and
the Purchaser shall purchase from the Company [_____________] shares of Common Stock (the “Shares”)
at a purchase price of $[_____] per share for a total purchase price of $[____________] (the
“Purchase Price”).

     2.2 Closing. The purchase and sale of the Shares being purchased by the Purchaser
shall take place at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One
Financial Center, Boston, MA 02111, at 10:00 a.m., local time, on [_____________], or at such
other location, date and time as may be agreed upon among the Purchaser and the Company (such
closing being called the “Closing” and such date and time being called the “Closing Date”). At the
Closing, the Company shall issue and deliver to the Purchaser a certificate in definitive form,
registered in the name of the Purchaser, representing the Shares being purchased by the Purchaser
at the Closing. As payment in full for the Shares being purchased by it under this Agreement, and
against delivery of the certificate therefor as aforesaid, on the Closing Date, the Purchaser (a)
shall deliver to the Company a check payable to the order of the Company in the amount of the
Purchase Price, (b) shall transfer such amount to the account of the Company by wire transfer, or
(c) shall deliver a combination of (a) and (b) above.

SECTION 3

Representations and Warranties and Certain Covenants of the Company

     Except as set forth in any disclosure schedules delivered herewith (which shall be numbered to
correspond with the sections of this Section 3), the Company hereby represents and warrants to and
covenants to the Purchaser as follows:

     3.1 Organization, Qualifications and Corporate Power. The Company is a corporation
duly incorporated, validly existing and in good standing under the laws of the State of Delaware
and the Company is duly licensed or qualified to transact business as a foreign corporation and is
in good standing in each jurisdiction in which the nature of the business transacted by it or the
character of the properties owned or leased by it requires such licensing or qualification, except
where failure to qualify would not have a material adverse effect on the business or financial
condition of the Company. The Company has the corporate power and authority to own and hold its
properties and to carry on its business as now conducted or as planned to be conducted in the
foreseeable future, to execute, deliver and perform this Agreement, the Rights Agreement and any
other agreements, documents or instruments contemplated hereby to which it is a party, to issue,
sell and deliver the Shares.

     3.2 Authorization of Agreements, Etc. 

3

 

          (a) The execution and delivery by the Company of this Agreement and the Rights Agreement, the
performance by the Company of its obligations hereunder and thereunder, and the issuance, sale and
delivery of the Shares have been duly authorized by all requisite corporate action and will not
violate any provision of law, any order of any court or other agency of government specifically
naming the Company, the Certificate of Incorporation, or the By-laws or any material provision of
any indenture, agreement or other instrument to which the Company is a party or by which it or its
assets are bound, or conflict with, result in a breach of or constitute (with due notice or lapse
of time or both) a default under any such indenture, agreement or other instrument, which
violation, conflict or default could have a material adverse effect on the Company, or result in
the creation or imposition of any material lien, charge, restriction, claim or encumbrance upon
any of the properties or assets of the Company.

          (b) The Shares have been duly authorized and the Shares, when issued in accordance with this
Agreement, will be validly issued, fully paid and nonassessable and free of all liens, charges,
restrictions, claims and encumbrances imposed by or through the Company except as set forth in the
Rights Agreement. None of the issuance, sale or delivery of the Shares is subject to any
preemptive right of stockholders of the Company or to any right of first refusal or other right in
favor of any person which has not been waived.

     3.3 Validity. This Agreement has been duly executed and delivered by the Company.
This Agreement constitutes and the Rights Agreement, when executed and delivered in accordance with
this Agreement, will constitute, the legal, valid and binding obligations of the Company,
enforceable in accordance with their respective terms subject to bankruptcy, insolvency,
reorganization, moratorium and other similar laws affecting the rights of creditors and to general
principles of equity.

     3.4 Consents. All consents, approvals, orders, or authorizations of, or
registrations, qualifications, designations, declarations, or filings with any federal or state
governmental authority, any party to a contract to which the Company or its assets are bound or any
other third party on the part of the Company required in connection with the consummation of the
transactions contemplated by this Agreement shall have been obtained prior to, and be effective as
of, the Closing (other than such filings under the “blue sky” law of any state governmental
authority and any federal securities law filings that may be made after the Closing, which such
filings shall be timely made, or such filings required by the Rights Agreement). The sale of the
Shares is not subject to any preemptive rights or rights of first refusal that have not been
properly waived or complied with.

     3.5 Subsidiaries. The Company has no subsidiaries other than as listed in an Exhibit
to the Registration Statement.

     3.6 Capitalization. The authorized and outstanding shares of capital stock and
options, warrants and other rights to purchase capital stock of the Company is as set forth in the
Prospectus. All issued and outstanding shares of the Company’s capital stock have been duly
authorized and validly issued, are fully paid and nonassessable, and were issued in compliance with
all applicable state and federal laws concerning the issuance of securities.

4

 

     3.7 Litigation. Except as set forth in the Prospectus and required to be disclosed
therein, there is no (i) action, suit, claim, proceeding or investigation pending or, to the best
of the Company’s knowledge, threatened against the Company, at law or in equity, or before or by
any federal, state, municipal or other governmental department, commission, board, bureau, agency
or instrumentality, domestic or foreign, (ii) arbitration proceeding relating to the Company
pending under collective bargaining agreements or otherwise or (iii) governmental inquiry pending
or, to the best of the Company’s knowledge, threatened against the Company (including without
limitation any inquiry as to the qualification of the Company to hold or receive any license or
permit), and to the best of the Company’s knowledge there is no basis for any of the foregoing.

     3.8 Financial Statements. The financial statements of the Company contained in the
Prospectus (i) are true and correct in all material respects, (ii) are in accordance with the books
and records of the Company, (iii) present fairly in all material respects the financial position of
the Company on as of the dates thereof and (iv) were prepared in accordance with United States
generally-accepted accounting principles (except, with respect to any interim Financial, for all of
the required footnotes and year end adjustments, which are not expected to be material).

     3.9 Taxes. The Company has accurately prepared in all material respects and timely
filed all federal, state, county and local tax returns required to be filed by it, and the Company
has paid all taxes required to be paid by it pursuant to such returns as well as all other taxes,
assessments and governmental charges which have become due or payable, including, without
limitation all taxes which the Company is obligated to withhold from amounts owing to employees,
creditors and third parties. All such taxes with respect to which the Company has become obligated
pursuant to elections made by the Company in accordance with generally accepted practice have been
paid and adequate reserves have been established for all taxes accrued but not payable.

     3.10 Intellectual Property. The Company owns or possesses adequate licenses or other
rights to use all patents, patent applications, trademarks, trademark applications, service marks,
service mark applications, trade names, copyrights, manufacturing processes, formulae, trade
secrets, customer lists and know how (collectively, “Intellectual Property”) necessary to the
conduct of its business as conducted consistent with the description of the Company’s business as
set forth in the Prospectus. Without diminishing the representation set forth in the preceding
sentence, the Company further represents that it has taken commercially reasonable steps to ensure
that all right, title and interest in any Intellectual Property which has been developed by key
employees or founders of the Company in their capacity as either employees or consultants to the
Company which is necessary for the conduct of the Company’s business as conducted has been
unconditionally assigned to the Company.

     3.11 Brokers. The Company has no contract, arrangement or understanding with any
broker, finder or similar agent with respect to the transactions contemplated by this Agreement.

     3.12 Insurance. The Company will use its commercially reasonable efforts to maintain
insurance with financially sound and reputable insurance companies or associations, in such amounts
and covering such risks as are adequate and customary for the type and scope of its

5

 

properties and business as currently conducted and as planned to be conducted in the
foreseeable future.

     3.13 Prospectus. The Prospectus does not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading in light of the circumstances under which they were made.

     3.14 Offering Valid. Assuming the accuracy of the representations and warranties of
Purchaser contained in Section 4 hereof, the offer, sale and issuance of the Shares will be exempt
from the registration requirements of the Act, and will have been registered or qualified (or are
exempt from registration and qualification) under the registration, permit or qualification
requirements of all applicable state securities laws.

SECTION 4

Representations and Warranties of Purchaser

     The Purchaser represents and warrants to the Company as follows:

     4.1 Experience. The Purchaser: (a) is an accredited investor within the definition of
Regulation D promulgated under the Act; (b) is experienced in evaluating and in investing in
developing biotechnology companies such as the Company and can afford a loss of its entire
investment; and/or (c) has a pre-existing personal or business relationship with the Company and/or
certain of its officers, directors or controlling persons of a nature and duration that enable it
to be aware of the character, business acumen and financial circumstance of such persons.

     4.2 Investment. The Purchaser is acquiring the Shares for investment for its own
account and not with the view to, or for resale in connection with, any distribution thereof. It
understands that the Shares have not been registered under the Act by reason of specified
exemptions form the registration provisions of the Act.

     4.3 Rule 144. The Purchaser acknowledges that the Shares must be held indefinitely
unless they are subsequently registered under the Act or an exemption from such registration is
available. It has been advised or is aware of the provisions of Rule 144 promulgated under the Act,
which permit limited release of shares purchased in a private placement subject to the satisfaction
of certain conditions, and is aware that such Rule may not become available for resale of the
Shares.

     4.4 Access to Data. The Purchaser has had an opportunity to discuss the Company’s
business, management and financial affairs with the Company’s management and has had the
opportunity to review the Company’s facilities.

     4.5 Brokers. The Purchaser has no contract, arrangement or understanding with any
broker, finder or similar agent with respect to the transactions contemplated by this Agreement.

     4.6 Authorization. The Purchaser has full power and authority to enter into and to
perform this Agreement in accordance with its terms. All action (corporate or otherwise) on the
part of the Purchaser necessary for the authorization, execution, delivery and performance by the
Purchaser of this Agreement and the consummation of the transactions contemplated herein has

6

 

been taken. This Agreement is valid and binding obligation of the Purchaser, enforceable in
accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and other
similar laws affecting the rights of creditors and to general principles of equity.

SECTION 5

Purchaser’s Conditions to Closing

     The Purchaser’s obligation to purchase Shares at the Closing is subject to the fulfillment to
its satisfaction on or prior to the Closing Date of each of the following conditions:

     5.1 Representations and Warranties. The representations and warranties contained in
Section 3 shall be true, complete and correct on and as of the Closing Date with the same effect as
though such representations and warranties had been made on and as of such date.

     5.2 Performance. The Company shall have performed and complied with all covenants,
agreements and conditions contained herein required to be performed or complied with by it prior to
or at the Closing Date.

     5.3 Legal Investment. At the time of the Closing, the purchase of the Shares shall be
legally permitted by all laws and regulations to which the Purchaser and the Company are subject.

     5.4 Rights Agreement. The Company and the Purchaser shall have executed and delivered
the Rights Agreement.

     5.5 Proceedings and Documents. All corporate and other proceedings in connection with
the transactions contemplated hereby and all documents and instruments incident to such
transactions shall be reasonably satisfactory in form and substance to the Purchaser and its
counsel. Prior to the Closing, the Company shall have obtained all consents or waivers, if any,
necessary to execute and deliver this Agreement and the Rights Agreement, issue the Shares and to
carry out the transactions contemplated hereby and thereby, and all such consents and waivers shall
be in full force and effect.

     5.6 Qualifications. All other authorizations, approvals or permits if any, of any
governmental authority or regulatory body of the United States or any state that are required prior
to and in connection with the lawful issuance and sale of the Shares pursuant to this Agreement
shall be effective on and as of the Closing Date.

     5.7 Qualified IPO. The Qualified IPO shall have been completed and the proceeds
therefrom shall have been received by the Company.

     5.8 Legal Opinion. The Purchaser shall have received from legal counsel to the
Company an opinion addressed to the Purchaser, dated as of the Closing Date, in form customarily
delivered in connection with the private placement of shares of common stock of a publicly traded
company and acceptable to the Purchaser, acting reasonably.

7

 

SECTION 6

Company’s Conditions to Closing

     The Company’s obligation to sell the Shares at the Closing is subject to the fulfillment on or
prior to the Closing Date of each of the following conditions:

     6.1 Representations and Warranties. The representations and warranties made by the
Purchaser pursuant to Section 4 hereof shall be true and correct when made and shall be true and
correct on the Closing Date.

     6.2 Performance. The Purchaser shall have performed and complied with all covenants,
agreements and conditions contained herein required to be performed or complied with by it prior to
or at the Closing Date.

     6.3 Legal Investment. At the time of the Closing, the purchase of the Shares shall be
legally permitted by all laws and regulations to which the Purchaser and the Company are subject.

     6.4 Rights Agreement. The Company and the Purchaser shall have executed and delivered
the Rights Agreement.

     6.5 Payment of Purchase Price. The Purchaser shall have delivered to the Company a
check or a transfer of funds to the account of the Company in the full amount of the Purchase
Price.

SECTION 7

Miscellaneous

     7.1 Governing Law. This Agreement shall be governed in all respects by the laws of
the State of Delaware without giving effect to principles of conflicts of law thereunder.

     7.2 Survival. The representations, warranties, covenants and agreements made herein
shall survive the closing of the transactions contemplated hereby. All statements as to factual
matters contained in any certificate or other instrument delivered by or on behalf of the Company
pursuant hereto in connection with the transactions contemplated hereby shall be deemed to be
representations and warranties by the Company hereunder solely as of the date of such certificate
or instrument.

     7.3 Successors and Assigns. Except as otherwise expressly provided herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns,
heirs, executors and administrators of the parties hereto. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement. Subject to the terms of this Agreement,
no party hereby may assign its rights or obligations hereunder (whether by operation of law or
otherwise, including by merger, asset sale, sale of stock or otherwise) without the prior written
consent of the other parties hereto.

8

 

     7.4 Entire Agreement; Amendment and Waiver. This Agreement (including the Schedules
and Exhibits hereto) and the other documents delivered pursuant hereto constitute the full and
entire understanding and agreement between the parties with regard to the subjects hereof and
thereof. Neither this Agreement nor any term hereof may be amended, modified, waived or terminated,
except by a written instrument signed by the Company and the Purchaser.

     7.5 Notices. Unless otherwise provided, all notices, requests, consents and other
communications hereunder shall be in writing, shall be addressed to the receiving party’s address
set forth below or to such other address as a party may designate by notice hereunder, and shall be
either (i) delivered by hand, (ii) made by telecopy or facsimile transmission, (iii) sent by
overnight courier, or (iv) sent by registered or certified mail, return receipt requested, postage
prepaid.

			
	If to the Company:	 	Archemix Corp.

300 Third Street

Cambridge, MA

Attn: Chief Executive Officer

Facsimile: (617) 621-9300

			
	With a copy to:	 	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, MA 02111

Attn: Jeffrey M. Wiesen, Esquire

Facsimile: (617) 542-2241

			
	If to the Purchaser:	 	Nuvelo, Inc.

201 Industrial Road, Suite 310

San Carlos, CA 94070

Attn: Chief Executive Officer

Facsimile: (650) 517-8058

			
	With a copy to:	 	Cooley Godward LLP

Five Palo Alto Square

3000 El Camino Real

Palo Alto, CA 94306-2155

Attn: John Geschke, Esquire

Facsimile: (650) 849-7400

or, in any such case, at such other address or addresses as shall have been furnished in
writing by such party to the others.

     All notices, requests, consents and other communications hereunder shall be deemed to have
been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the
address of such party set forth above, (ii) if made by telecopy or facsimile transmission, at the
time that receipt thereof has been acknowledged by electronic confirmation or otherwise, (iii) if
sent by overnight courier, on the next business day following the day such notice is

9

 

delivered to the courier service, or (iv) if sent by registered or certified mail, on the fifth business
day following the day such mailing is made.

     7.6 Delays or Omissions. No delay or omission to exercise any right, power or remedy
accruing to any holder of any shares upon any breach or default of the Company under this Agreement
shall impair any such right, power or remedy of such holder nor shall it be construed to be a
waiver of any such breach or default, or an acquiescence therein, or in any similar breach or
default occurring thereafter; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of any holder or any breach or default
under this Agreement, or any waiver on the part of any holder of any provisions or conditions of
this Agreement must be made in writing and shall be effective only to the extent specifically set
forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to
any holder, shall be cumulative and not alternative.

     7.7 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision shall be excluded from this Agreement and the
balance of the Agreement shall be interpreted as if such provision were so excluded and shall be
enforceable in accordance with its terms.

     7.8 Interpretation. The parties hereby acknowledge and agree that: (i) each party
and its counsel reviewed and negotiated the terms and provisions of this Agreement and have
contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are
resolved against the drafting party shall not be employed in the interpretation of this Agreement;
and (iii) the terms and provisions of this Agreement shall be construed fairly as to all parties
hereto and not in a favor of or against any party, regardless of which party was generally
responsible for the preparation of this Agreement.

     7.9 Further Assurances. From and after the date of this Agreement, the Company and
the Purchaser shall execute and deliver such instruments, documents or other writings as may be
reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and
purposes of this Agreement.

     7.10 Headings. The headings and subheadings used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this Agreement.

     7.11 Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. One or more counterparts of this Agreement may be delivered via telecopier with the
intention that they shall each have the same effect as an original counterpart hereof.

[Remainder of Page Intentionally Left Blank]

10

 

     IN WITNESS WHEREOF, the parties have duly executed this Stock Purchase Agreement as of the
date first above written.

	 	 	 	 	 
	 	COMPANY:

ARCHEMIX CORP.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 
	 	PURCHASER:

NUVELO, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 

11

 

	 	 	 	 	 

Exhibit A

Registration Rights Agreement

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]